Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). 2006

Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
Molecular Simulation Engineering Laboratory, Department of Chemical Engineering, University of Trieste, Piazzale Europa 1, 34127 Trieste, Italy.

In human tumors, p53 is often disabled by mutations in its DNA-binding domain and is thus inactive as a transcription factor. Alternatively, MDM2 gene amplification or up-regulation represents a mechanism of p53 wild-type inactivation, mainly reported in soft tissue sarcomas. In a previous TP53 analysis carried out on sporadic and NF1-related malignant peripheral nerve sheath tumors, in two cases, we observed the occurrence of C238Y missense mutation, leading to p53 stabilization unexpectedly coupled with immunophenotypic MDM2 overexpression. To investigate this TP53 missense mutation not yet functionally characterized in mammalian cell, we did MDM2 Southern blot and p53(C238Y)/MDM2 biochemical and functional analyses followed by molecular modeling. The results showed a lack of MDM2 gene amplification, evidence of p53-MDM2 protein complexes, and presence of a p53 that retains the ability to become phosphorylated on Ser15 and to induce the transcription of p21(waf1). Additional molecular modeling data highlighted the structural similarities between p53(C238Y) and wild-type p53, further supporting that the p53(C238Y) mutant still retains functional wild-type p53 properties.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
January 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
January 1991, Molecular and cellular biology,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
January 2001, Journal of cellular biochemistry,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
October 1993, Cancer research,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
February 1994, Molecular and cellular biology,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
September 1997, Proceedings of the National Academy of Sciences of the United States of America,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
February 1993, The EMBO journal,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
July 2001, Molecular therapy : the journal of the American Society of Gene Therapy,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
September 1996, The EMBO journal,
Marco Ferrone, and Federica Perrone, and Elena Tamborini, and Maria Silvia Paneni, and Maurizio Fermeglia, and Simona Suardi, and Elisa Pastore, and Domenico Delia, and Marco A Pierotti, and Sabrina Pricl, and Silvana Pilotti
December 2009, Technology in cancer research & treatment,
Copied contents to your clipboard!